Wall Street Zen Upgrades Enliven Therapeutics (NASDAQ:ELVN) to Hold

Enliven Therapeutics (NASDAQ:ELVN) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other brokerages have also recently issued reports on ELVN. Morgan Stanley initiated coverage on shares of Enliven Therapeutics in a report on Friday, October 2nd. They issued an “overweight” rating and a $70.00 target price for the company. Guggenheim reiterated a “buy” rating and set a $78.00 price target on shares of Enliven Therapeutics in a research note on Friday. Stifel Nicolaus lifted their price target on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. started coverage on shares of Enliven Therapeutics in a research report on Thursday, October 1st. They issued an “overweight” rating and a $75.00 price target for the company. Finally, HC Wainwright upped their price objective on shares of Enliven Therapeutics from $65.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, October 19th. Ten investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Enliven Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $75.44.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $49.43 on Friday. The company has a market capitalization of $3.64 billion, a price-to-earnings ratio of -28.91 and a beta of 0.34. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $62.32. The stock has a 50 day moving average price of $47.25 and a 200 day moving average price of $43.08.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09. On average, equities analysts anticipate that Enliven Therapeutics will post -1.79 EPS for the current fiscal year.

Insider Buying and Selling

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the transaction, the chief financial officer owned 38,000 shares of the company’s stock, valued at $1,462,240. The trade was a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the sale, the director owned 13,000 shares of the company’s stock, valued at approximately $606,710. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 31,054 shares of company stock worth $1,493,823 in the last 90 days. 3.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its stake in shares of Enliven Therapeutics by 70.9% during the first quarter. Dimensional Fund Advisors LP now owns 681,715 shares of the company’s stock worth $26,714,000 after buying an additional 282,822 shares during the period. Legal & General Group Plc purchased a new position in shares of Enliven Therapeutics during the second quarter worth about $1,671,000. Avidity Partners Management LP grew its holdings in shares of Enliven Therapeutics by 185.1% during the first quarter. Avidity Partners Management LP now owns 400,000 shares of the company’s stock worth $15,680,000 after buying an additional 259,700 shares during the last quarter. Nicholas Investment Partners LP acquired a new position in Enliven Therapeutics in the 2nd quarter valued at about $19,870,000. Finally, Stempoint Capital LP acquired a new position in Enliven Therapeutics in the 1st quarter valued at about $14,247,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth.

The company’s pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2.

Enliven is based in Boulder, Colorado.